Princeton, NJ and Paris, France, March 27, 2008: Laureate Pharma, Inc., a full-function facility of biopharmaceutical development and protein manufacturing, claimed nowadays that it has signed a contract with Cytheris SA, a clinical phase of biopharmaceutical facility oriented on trials and development of new treatment for immune stimulation. According to the contract, Laureate will produce Cytheris’ lead product candidate, Interleukin-7 (IL-7), a complete glycated recombinant human protein and crucial growth-stimulating factor for immune T-cell recovery, for utilization in continuing international clinical research at the moment being carried out for HIV, HCV and cancer treatment. Terms and conditions of the contract were not revealed.
“Our specific experience in the production of monoclonal antibodies transforms us into a perfect partner to maintain ARIUS and the manufacturing of their Trop-2 Signal Transduction Antibody,” said Zachary Hodgson, Ph.D., President & CEO of Laureate.
“The initiation of producing for our second drug candidate exhibits our capability to execute on our milestones and transform into multiple partners from the ARIUS pipeline of drug candidates forward,” said Dr. Oliver Rowe, President and Chief Executive Officer of ARIUS. “Laureate Pharma has a tracking record of trials in biopharmaceutical producing, including priorities in both clinical and commercial supplements and will ensure us with a supply of our Trop-2 targeting drug significant to start for our preclinical investigations in the first quarter of 2008 in preparation for human clinical research.”
ARIUS’ Trop-2 Signal Transduction Antibody Program has manufactured the only unconjugated antibody at the moment in development targeting this novel marker. Trop-2 is a protein shown on the cell-surface and found in many cancer indications inclusively of pancreatic, colon, breast and prostate cancer. The main aim is a key to the expansive MAPK path. Of more than 900 articles look at for oral presentation at the October 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, the abstract on Trop-2 was one of 12 chosen. The Trop-2 Signal Transduction Program was updated by means of ARIUS’ proprietary FunctionFIRST™ technology, which chooses antibodies oriented on their capability to damage and destroy cancer cells.
About Laureate Pharma, Inc.
Laureate Pharma is a full-function facility of biopharmaceutical development and protein manufacturing based in Princeton, New Jersey. Laureate Pharma proposes superior services in bioprocessing that speed up new products from development through production. Laureate ensures a wide assortment of specific services from processing design and development to large-scale cGMP manufacturing, clearance, aseptic filling, testing, validation, analytical services, and regulatory maintenance. Laureate is oriented on 2 active divisions of the biopharmaceutical branches: monoclonal antibodies and recombinant protein products. Laureate Pharma, Inc. is a wholly owned subsidiary of Safeguard Scientifics, Inc.
ARIUS is a biotechnology facility exploring and developing the next wave of antibody therapies. Founded in 1999, ARIUS has created a proprietary technology pattern, FunctionFIRST™ that rapidly specifies and chooses antibodies ground on their functional priority to have an effect on disorders. This antibody generation engine is the key element of ARIUS to compose a portfolio of more than 500 antibody candidates. Additionally to the antibodies, it is exploring in-house, ARIUS has continuing partnerships with the main biotechnology and preparation development companies.